These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 38752448)

  • 1. Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis.
    Lian D; Gan Y; Xiao D; Xuan D; Chen Y; Yang Y
    Cancer Med; 2024 May; 13(10):e7243. PubMed ID: 38752448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
    Abraham I; Calamia M; Alkhatib N; Pondel M; MacDonald K
    J Med Econ; 2024; 27(sup3):9-23. PubMed ID: 39016811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis.
    Tian K; Han J; Wang Z; Chen J
    Oral Oncol; 2022 May; 128():105842. PubMed ID: 35428025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
    Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi Y; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Wang S; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Luo X; Wang X; Tang X; Feng H; Yao S; Keegan P; Xu RH
    JAMA; 2023 Nov; 330(20):1961-1970. PubMed ID: 38015220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma.
    Jin C; Zheng H; Zhan M; Wen F; Xu T
    Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):577-584. PubMed ID: 31720816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
    MacDonald K; Pondel M; Abraham I
    J Med Econ; 2024; 27(sup3):1-8. PubMed ID: 38488887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.
    Tang YK; Xu Z; Ye ZM; Li SR; Zhou Q
    Head Neck; 2024 Jan; 46(1):5-14. PubMed ID: 37846175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
    Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
    Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis.
    Cai H; Huang L; Zheng Z
    Front Public Health; 2024; 12():1421826. PubMed ID: 39135924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States.
    Xiang G; Huang Y; Gan L; Wang L; Ding Y; Wu Y; Xing H; Liu Y
    Front Immunol; 2024; 15():1426024. PubMed ID: 39346914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
    Chen X; Liang W; Wan N; Zhang L; Yang Y; Jiang J; Zhang T
    Oral Oncol; 2019 Jul; 94():80-85. PubMed ID: 31178217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China.
    Zhao Z; Chen T; Zhou Z; Guo R; Liu Q
    BMJ Open; 2023 Dec; 13(12):e071832. PubMed ID: 38110377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
    Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi YR; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Liu Z; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Feng H; Yao S; Keegan P; Xu RH
    Nat Med; 2021 Sep; 27(9):1536-1543. PubMed ID: 34341578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis.
    Liang X; Meng M; Qin S; Chen X; Li Y
    Sci Rep; 2024 Jun; 14(1):14496. PubMed ID: 38914660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma.
    Zou X; Ding X; Feng ZK; Ouyang YF; Li HF; Wen K; Wang ZQ; Liu YP; Liu YL; Zhang WJ; Yang Q; Chen SY; Xie YL; Xie RQ; Lin C; Gu CM; Huang PY; Sun R; Hua YJ; You R; Chen MY
    Cell Rep Med; 2024 Oct; 5(10):101779. PubMed ID: 39413735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
    Rui M; Shi F; Shang Y; Meng R; Li H
    Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma.
    Zhang L; Su H; Liang X; Chen X; Li Y
    Sci Rep; 2024 Jul; 14(1):17734. PubMed ID: 39085374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer.
    Wang H; Long Y; Xu Y; Liao L; Zhou Y
    Front Public Health; 2023; 11():1137255. PubMed ID: 37033059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of toripalimab plus chemotherapy for advanced esophageal squamous cell carcinoma.
    Xu K; Wu H; Zhou C; Bao Y; Yu M; Zhang L; Li X
    Int J Clin Pharm; 2023 Jun; 45(3):641-649. PubMed ID: 36800145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.